Journal ArticleDOI
Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment.
Reads0
Chats0
About:
This article is published in Critical Care Medicine.The article was published on 1997-07-01. It has received 653 citations till now. The article focuses on the topics: Sepsis & Septic shock.read more
Citations
More filters
Journal ArticleDOI
The pathophysiology and treatment of sepsis.
TL;DR: This review examines evolving concepts of sepsis and discusses new and potential therapies, including therapy with activated protein C, stringent control of blood glucose, and early goal-directed therapy to treat cellular oxygen deficit.
Journal ArticleDOI
Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock
Djillali Annane,Véronique Sébille,C. Charpentier,Pierre-Edouard Bollaert,Bruno François,Jean-Michel Korach,Gilles Capellier,Yves Cohen,Elie Azoulay,Gilles Troché,Philippe Chaumet-Riffaut,Eric Bellissant +11 more
TL;DR: In this trial, a 7-day treatment with low doses of hydrocortisone and fludrocort isone significantly reduced the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events.
Journal ArticleDOI
The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome
TL;DR: The goals of this article are to provide an overview of sepsis and its complications, discuss the role of the endothelium in orchestrating the host response insepsis, and emphasize the potential value of the artery as a target for sepsi therapy.
Journal ArticleDOI
A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin.
Djillali Annane,Véronique Sébille,Gilles Troché,Jean Claude Raphael,Philippe Gajdos,Eric Bellissant +5 more
TL;DR: The data suggest that a short corticotropin test has a good prognostic value and could be helpful in identifying patients with septic shock at high risk for death.
Journal ArticleDOI
Bacterial lipopolysaccharides and innate immunity
TL;DR: The elucidation of structure-activity correlations in LPS and lipid A has not only contributed to a molecular understanding of both immunostimulatory and toxic septic processes, but has also re-animated the development of new pharmacological and immunostIMulatory strategies for the prevention and therapy of infectious and malignant diseases.
References
More filters
Journal ArticleDOI
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis.
Joseph C. Lee,Jeffrey T. Laydon,Peter C. McDonnell,Timothy Gallagher,Sanjay Kumar,David W. Green,Dean E. McNulty,M. J. Blumenthal,J. R. Heys,S. W. Landvatter,James E. Strickler,Megan M. McLaughlin,I. R. Siemens,Seth M. Fisher,George P. Livi,John R. White,Jerry L. Adams,Peter Young +17 more
TL;DR: Production of interleukin-1 and tumour necrosis factor from stimulated human monocytes is inhibited by a new series of pyridinyl-imidazole compounds, suggesting that the CSBPs are critical for cytokine production.
Journal ArticleDOI
A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.
Roger C. Bone,Charles J. Fisher,Terry P. Clemmer,Gus J. Slotman,Craig A. Metz,Robert A. Balk +5 more
TL;DR: It is concluded that the use of high-dose corticosteroids provides no benefit in the treatment of severe sepsis and septic shock.
Journal ArticleDOI
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein
Charles J. Fisher,Jan M. Agosti,Steven M. Opal,Stephen F. Lowry,Robert A. Balk,Jerald C. Sadoff,Edward Abraham,Roland M. H. Schein,Ernest Benjamin +8 more
TL;DR: In patients with septic shock, treatment with the TNFR:Fc fusion protein does not reduce mortality, and higher doses appear to be associated with increased mortality.
Journal ArticleDOI
Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
Charles J. Fisher,JF Dhainaut,Steven M. Opal,John Pribble,Robert A. Balk,Gus J. Slotman,Thomas J. Iberti,EC Rackow,Shapiro Mj,Greenman Rl +9 more
TL;DR: Primary and retrospective analyses of efficacy suggest that treatment with rhIL-1ra results in a dose-related increase in survival time among patients with sepsis who have organ dysfunction and/or a predicted risk of mortality of 24% or greater.
Journal ArticleDOI
The Effects of Ibuprofen on the Physiology and Survival of Patients with Sepsis
Gordon R. Bernard,Arthur P. Wheeler,James A. Russell,Roland M. H. Schein,Warren R. Summer,Kenneth P. Steinberg,William J. Fulkerson,Patrick Wright,Brian W. Christman,William D. Dupont,Stanley B. Higgins,Bridget B. Swindell +11 more
TL;DR: Treatment with ibuprofen reduces levels of prostacyclin and thromboxane and decreases fever, tachycardia, oxygen consumption, and lactic acidosis, but it does not prevent the development of shock or the acute respiratory distress syndrome and does not improve survival.